Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

C. F. LeMaistre; C. M. Meneghetti; A. B. Deisseroth; M. G. Rosenblum; J. M. Reuben; D. R. Parkinson; K. Parker; J. P. Shaw; T. Woodworth

doi:10.1016/0140-6736(91)92788-4

Therapeutic effects of genetically engineered toxin (DAB₄₈₆IL-2) in patient with chronic lymphocytic leukaemia

C. F. LeMaistre
, C. M. Meneghetti
, A. B. Deisseroth
, M. G. Rosenblum
, J. M. Reuben
, D. R. Parkinson
, K. Parker
, J. P. Shaw
, T. Woodworth

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

In DAB₄₈₆IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB₄₈₆IL-2.

Original language	English (US)
Pages (from-to)	1124-1125
Number of pages	2
Journal	The Lancet
Volume	337
Issue number	8750
DOIs	https://doi.org/10.1016/0140-6736(91)92788-4
State	Published - May 11 1991

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/0140-6736(91)92788-4

Cite this

@article{c6acfaa458004b61b1e5bfcd20e46543,

title = "Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia",

abstract = "In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.",

author = "LeMaistre, \{C. F.\} and Meneghetti, \{C. M.\} and Deisseroth, \{A. B.\} and Rosenblum, \{M. G.\} and Reuben, \{J. M.\} and Parkinson, \{D. R.\} and K. Parker and Shaw, \{J. P.\} and T. Woodworth",

year = "1991",

month = may,

day = "11",

doi = "10.1016/0140-6736(91)92788-4",

language = "English (US)",

volume = "337",

pages = "1124--1125",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8750",

}

TY - JOUR

T1 - Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

AU - LeMaistre, C. F.

AU - Meneghetti, C. M.

AU - Deisseroth, A. B.

AU - Rosenblum, M. G.

AU - Reuben, J. M.

AU - Parkinson, D. R.

AU - Parker, K.

AU - Shaw, J. P.

AU - Woodworth, T.

PY - 1991/5/11

Y1 - 1991/5/11

N2 - In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

AB - In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

UR - https://www.scopus.com/pages/publications/0025853356

UR - https://www.scopus.com/pages/publications/0025853356#tab=citedBy

U2 - 10.1016/0140-6736(91)92788-4

DO - 10.1016/0140-6736(91)92788-4

M3 - Article

C2 - 1674015

AN - SCOPUS:0025853356

SN - 0140-6736

VL - 337

SP - 1124

EP - 1125

JO - The Lancet

JF - The Lancet

IS - 8750

ER -

Therapeutic effects of genetically engineered toxin (DAB₄₈₆IL-2) in patient with chronic lymphocytic leukaemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this